AI diagnostic
The algorithms are used to detect valvular heart disease.
It detects signs of inflammation with over 90% accuracy.
It plans to secure more regulatory approvals for its AI pathology platform.
This follows its earlier approvals from the US, Europe, Japan and Taiwan.
Also, Global Health is deploying its patient engagement and data solutions to the upcoming George Centre.
It can diagnose diabetic retinopathy and diabetic macular oedema in 5-10 seconds.
They will provide the first access to an AI-enabled minimal residual disease test in India.
Two variants of the Annalise CXR Edge products will be offered in Australia.
The AI platform can predict a person's risk of having a stroke or a heart attack in the next five years.
The AI tech can spot signs of pancreatic cancer from non-contrast CT images.